Anna Beryozkina

The recipient of a bachelor's degree in psychology from McGill University, Anna Beryozkina subsequently completed a prepharmacy program at the University of Pittsburgh and earned a doctor of pharmacy from the Massachusetts College of Pharmacy and Health Sciences. After completing fellowships in clinical pharmacology, regulatory affairs program management, and regulatory intelligence, Dr. Anna Beryozkina was hired as a regulatory program manager with San Francisco, California's Genentech, Inc. Through five years in this role, she was responsible for preparing the project team to answer questions from the FDA and providing regulatory input for oncology-based molecules to the protocol execution teams (PET) and study management teams, among other tasks.

Dr. Anna Beryozkina was recently promoted to associate clinical scientist and now serves as the lead clinical science representative on the PET, while also working alongside the PET leader and clinical science team leader to coordinate efforts between the PET and clinical study teams as well as manage any potential issues that arise. Supplementing her professional pursuits, Dr. Beryozkina attends the annual conferences of the American College of Rheumatology, American Society of Clinical Oncology, and European League Against Rheumatism.